Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

EyePoint Pharmaceuticals (EYPT) Current Deferred Revenue: 2011-2017

Historic Current Deferred Revenue for EyePoint Pharmaceuticals (EYPT) over the last 7 years, with Jun 2017 value amounting to $50,000.

  • EyePoint Pharmaceuticals' Current Deferred Revenue fell 94.06% to $30,000 in Q4 2018 from the same period last year, while for Dec 2018 it was $30,000, marking a year-over-year decrease of 94.06%. This contributed to the annual value of $50,000 for FY2017, which is 65.99% down from last year.
  • EyePoint Pharmaceuticals' Current Deferred Revenue amounted to $50,000 in FY2017, which was down 65.99% from $147,000 recorded in FY2016.
  • In the past 5 years, EyePoint Pharmaceuticals' Current Deferred Revenue ranged from a high of $5.6 million in FY2013 and a low of $33,000 during FY2015.
  • Its 3-year average for Current Deferred Revenue is $76,667, with a median of $50,000 in 2017.
  • As far as peak fluctuations go, EyePoint Pharmaceuticals' Current Deferred Revenue plummeted by 97.54% in 2014, and later spiked by 345.45% in 2016.
  • Yearly analysis of 5 years shows EyePoint Pharmaceuticals' Current Deferred Revenue stood at $5.6 million in 2013, then tumbled by 97.54% to $138,000 in 2014, then tumbled by 76.09% to $33,000 in 2015, then surged by 345.45% to $147,000 in 2016, then plummeted by 65.99% to $50,000 in 2017.